1
===============================================================================
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
----------------
FORM 10-Q
(MARK ONE)
[ X ] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
FOR THE QUARTERLY PERIOD ENDED MARCH 31, 1997
OR
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
FOR THE TRANSITION PERIOD FROM ___________________ TO ______________________
COMMISSION FILE NUMBER 0-19371
PHARMCHEM LABORATORIES, INC.
(Exact name of registrant as specified in its charter)
CALIFORNIA 77-0187280
(State or other jurisdiction (I.R.S. Employer
of incorporation or organization) Identification
Number)
1505-A O'BRIEN DRIVE
MENLO PARK, CALIFORNIA 94025
(Address of principal executive offices) (Zip Code)
REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE: (415) 328-6200
Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such report(s), and (2) has been subject to such
filing requirements for the past 90 days. Yes [X] No [ ]
As of April 30, 1997, the registrant had outstanding 5,730,564 shares
of Common Stock, no par value.
================================================================================
2
PHARMCHEM LABORATORIES, INC.
QUARTERLY REPORT ON FORM 10-Q
INDEX
PAGE
PART I. FINANCIAL INFORMATION
Item 1. Condensed Consolidated Financial Statements ...............................................3
Condensed Consolidated Interim Balance Sheets at
March 31, 1997 (unaudited) and December 31, 1996 (audited).................................4
Condensed Consolidated Interim Statements of Operations
(unaudited) for the Three Months ended March 31, 1997 and 1996.............................5
Condensed Consolidated Interim Statements of
Cash Flows (unaudited) for the Three Months ended
March 31, 1997 and 1996 ..................................................................6
Notes to Condensed Consolidated Interim Financial Statements...............................7
Item 2. Management's Discussion and Analysis of Financial Condition
and Results of Operations .................................................................8
PART II. OTHER INFORMATION
Item 6. Exhibits and Reports on Form 8-K ........................................................11
SIGNATURE ..........................................................................................12
2
3
PART I. FINANCIAL INFORMATION
1. Condensed Consolidated Financial Statements
The condensed consolidated interim financial statements included herein
have been prepared by the Company, without audit, pursuant to the rules and
regulations of the Securities and Exchange Commission. Certain information and
footnote disclosures normally included in financial statements prepared in
accordance with generally accepted accounting principles have been condensed or
omitted pursuant to such rules and regulations, although the Company believes
that the disclosures made are adequate to make the information presented not
misleading. It is suggested that the condensed consolidated interim financial
statements be read in conjunction with the consolidated financial statements and
the notes thereto for the year ended December 31, 1996 included in the Company's
Annual Report on Form 10-K.
These financial statements have been prepared in all material respects
in conformity with the standards of accounting measurements set forth in
Accounting Principles Board Opinion No. 28, "Interim Financial Reporting," and
the rules and regulations as specified in the Securities and Exchange Act of
1934 and reflect all adjustments, consisting only of normal recurring
adjustments which, in the opinion of management, are necessary to summarize
fairly the Company's consolidated financial position, the results of its
operations and its cash flows for the periods presented. The results of
operations for such interim periods are not necessarily indicative of the
results to be expected for the full year.
3
4
PHARMCHEM LABORATORIES, INC.
CONDENSED CONSOLIDATED INTERIM BALANCE SHEETS
March 31, December 31,
1997 1996
----------------- ---------------
(Unaudited) (Audited)
ASSETS (In thousands)
------
CURRENT ASSETS
Cash and cash equivalents $ 403 $ 240
Accounts receivable, net 7,370 8,168
Inventory 907 1,014
Other current assets 893
1,122
----------------- ---------------
TOTAL CURRENT ASSETS 9,573 10,544
----------------- ---------------
PROPERTY AND EQUIPMENT, net 6,437 6,578
OTHER ASSETS 981 986
GOODWILL, net 3,314 3,360
----------------- ---------------
TOTAL ASSETS $ 20,305 $ 21,468
================= ===============
LIABILITIES AND SHAREHOLDERS' EQUITY
------------------------------------
CURRENT LIABILITIES
Current portion of long-term debt $ 2,643 $ 2,335
Accounts payable 2,333 3,238
Accrued compensation 871 998
Accrued collectors and other liabilities 2,244 2,266
----------------- ---------------
TOTAL CURRENT LIABILITIES 8,091 8,837
----------------- ---------------
LONG TERM DEBT, net of current portion 1,092 1,205
DEFERRED CREDITS 155 139
SHAREHOLDERS' EQUITY
Common stock, no par value, 10,000 shares authorized, 5,725 and
5,695 shares issued and outstanding at March 31, 1997
and December 31, 1996, respectively 18,973 18,915
Accumulated deficit (8,006) (7,628)
----------------- ---------------
TOTAL SHAREHOLDERS' EQUITY 10,967 11,287
----------------- ---------------
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY $ 20,305 $ 21,468
================= ===============
The accompanying notes are an integral part of these condensed consolidated
interim financial statements.
4
5
PHARMCHEM LABORATORIES, INC.
CONDENSED CONSOLIDATED INTERIM STATEMENTS OF OPERATIONS
(Unaudited)
Three Months Ended
March 31,
------------------------------
1997 1996
------------ ------------
(In thousands, except per share amounts)
NET SALES $ 9,058 $ 9,867
COST OF SALES 7,156 7,626
------------ ------------
GROSS PROFIT 1,902 2,241
OPERATING EXPENSES
Selling, general and administrative 2,063 1,883
Marketing rights and research costs 84 451
Amortization of goodwill 46 46
------------ ------------
Total operating expenses 2,193 2,380
------------ ------------
LOSS FROM OPERATIONS (291) (139)
Interest expense (85) (112)
Other (expense) income, net (2) 73
------------ ------------
(87) (39)
------------ ------------
LOSS BEFORE PROVISION FOR INCOME TAXES (378) (178)
PROVISION FOR INCOME TAXES - -
------------ ------------
NET LOSS $ (378) $ (178)
============ ============
NET LOSS PER SHARE $ (0.07) $ (0.03)
============ ============
Weighted average number of common shares outstanding 5,714 5,594
============ ============
The accompanying notes are an integral part of these condensed consolidated
interim financial statements.
5
6
PHARMCHEM LABORATORIES, INC.
CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS
(Unaudited)
Three Months Ended
March 31,
-----------------------------
1997 1996
------------- -------------
(In thousands)
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss $ (378) $ (178)
Adjustments to reconcile net loss to net cash provided by operating
activities:
Depreciation and amortization 473 418
Loss (gain) on disposition of property and equipment 6 (50)
Change in operating assets and liabilities:
Accounts receivable, net 798 118
Inventory 107 (3)
Other current assets 229 14
Accounts payable and other accrued liabilities (1,054) 218
Deferred credits 16 -
------------- -------------
Change in operating assets and liabilities 575 715
------------- -------------
Net cash provided by operating activities 197 537
------------- -------------
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment (292) (1,511)
Proceeds from sale of property and equipment - 230
Decrease (increase) in other assets 5 (80)
------------- -------------
Net cash used in investing activities (287) (1,361)
------------- -------------
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from revolving line of credit and long-term debt 4,107 4,947
Principal payments on revolving line of credit and long-term debt (3,912) (4,526)
Proceeds from exercise of stock options 58 17
------------- -------------
Net cash provided by financing activities 253 438
------------- -------------
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS 163 (386)
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD 240 647
------------- -------------
CASH AND CASH EQUIVALENTS AT END OF PERIOD $ 403 $ 261
============= =============
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Cash paid for interest $ 33 $ 106
============= =============
Cash paid for taxes $ 6 $ 27
============= =============
The accompanying notes are an integral part of these condensed consolidated
interim financial statements.
6
7
PHARMCHEM LABORATORIES, INC.
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
(Unaudited)
1. Net Loss per Share
Net loss per share data has been computed only on the weighted average
number of common shares outstanding during the period. Common equivalent shares,
which represent shares issuable upon the exercise of outstanding options were
excluded from the calculation of the loss per share because the effect of
including such shares in the computation would be anti-dilutive.
The Financial Accounting Standards Board recently issued Statement of
Financial Accounting Standards ("SFAS") No. 128 "Earnings Per Share." SFAS No.
128 requires the presentation of basic earnings per share ("EPS") and, for
companies with complex capital structures, diluted EPS. SFAS No. 128 is
effective for annual and interim periods ending after December 15, 1997 and
requires restatement of all prior-period EPS data presented. The Company expects
basic EPS will be equivalent to primary EPS as presented in the accompanying
condensed consolidated financial statements.
2. Debt
In February and May 1997, PharmChem amended its revolver and term loan
credit agreement ("Credit Agreement") with a bank with respect to certain
financial covenants. The amendments provide for greater flexibility with respect
to covenants for quarterly profitability and cash flow coverage. As of March 31,
1997, the Company was in compliance with all covenants of the Credit Agreement.
7
8
Item 2. Management's Discussion and Analysis of Financial Condition and Results
of Operations
FORWARD LOOKING STATEMENTS
"Management's Discussion and Analysis of Financial Condition and
Results of Operations" contains forward-looking statements within the meaning
of Section 21E of the Securities Exchange Act of 1934 and Section 27A of the
Securities Act of 1933, which are subject to the "safe harbor" created by these
Sections. The Company's actual future results could differ materially from
those projected in the forward-looking statements. Some factors which could
cause future actual results to differ materially from the Company's recent
results and those projected in the forward-looking statements are described in
the Company's Annual Report on Form 10-K for the year ended December 31, 1996.
The Company assumes no obligation to update the forward-looking statements or
such factors.
RESULTS OF OPERATIONS
The following table sets forth for the periods indicated certain
financial data (dollars in thousands):
Three Months Ended March 31,
-------------------------------------------------------------
1997 1996 1997 1996
------------- ------------- -------------- --------------
NET SALES: (As a percentage of sales)
Public and private employers $ 3,829 $ 4,324 42.3% 43.8%
Criminal justice agencies 3,608 3,945 39.8 40.0
Drug rehabilitation programs and other 386 545 4.3 5.5
Product sales 258 78 2.9 0.8
Medscreen 977 975 10.7 9.9
------------- ------------- -------------- --------------
Total net sales 9,058 9,867 100.0 100.0
COST OF SALES 7,156 7,626 79.0 77.3
------------- ------------- -------------- --------------
GROSS PROFIT 1,902 2,241 21.0 22.7
------------- ------------- -------------- --------------
OPERATING EXPENSES:
Selling, general and administrative 2,063 1,883 22.8 19.1
Marketing rights and research 84 451 0.9 4.5
Amortization of goodwill 46 46 0.5 0.5
------------- ------------- -------------- --------------
Total operating expenses 2,193 2,380 24.2 24.1
------------- ------------- -------------- --------------
LOSS FROM OPERATIONS (291) (139) (3.2) (1.4)
------------- ------------- -------------- --------------
OTHER EXPENSE, net (87) (39) (1.0) (0.4)
------------- ------------- -------------- --------------
NET LOSS $ (378) $ (178) (4.2)% (1.8)%
============= ============= ============== ==============
8
9
Net sales decreased $809,000 (8.2%) to $9,058,000 in 1997 from $9,867,000
in 1996. This decrease is principally attributed to sales decreases of $495,000
(11.4%) to public and private employers, $337,000 (8.5%) to criminal justice
agencies and $159,000 (29.2%) to drug rehabilitation programs, which more than
offset an increase of $180,000 (230.8%) in PharmScreenTM and PharmChekTM product
sales. Sales increased slightly at Medscreen. The Company's domestic specimen
volume decreased 16.5% from 1996 levels. The volume reduction reflects the
August 1996 loss of the U.S. Army contract and the recent trend of criminal
justice agencies toward purchasing products, such as PharmScreenTM and
PharmChekTM, in lieu of traditional laboratory testing services.
Cost of sales decreased $470,000 (6.2%) to $7,156,000 in 1997 from
$7,626,000 in 1996, due primarily to a reduction of variable expenses offset by
the underabsorption of fixed expenses resulting from lower volume. Cost of
sales as a percentage of net sales increased to 79.0% in 1997 from 77.3% in
1996. Gross profit as a percentage of net sales decreased to 21.0% in 1997 from
22.7% in 1996.
Selling, general and administrative (SG&A) expenses increased $180,000
(9.6%) to $2,063,000 in 1997 from $1,883,000 in 1996. This increase reflects the
Company's continued investment in the marketing, information systems and
administrative infrastructure. SG&A expenses as a percentage of net sales
increased to 22.8% in 1997 from 19.1% in 1996.
Marketing rights and research costs decreased $367,000 (81.4%) to
$84,000 in 1997 from $451,000 in 1996. These expenses include the cost
associated with the development and commercialization of new laboratory methods
and other drug testing systems. This decrease was due primarily to significant
expenditures in the prior year for PharmChek(TM). Marketing rights and research
costs as a percentage of net sales decreased to 0.9% in 1997 from 4.5% in 1996.
Loss from operations increased to $291,000 in 1997 from $139,000 in
1996. Other expenses, including interest expense and interest income,
increased to $87,000 in 1997 from $39,000 in 1996, reflecting lower interest
expense offset by a decrease in interest income and the 1996 sale of equipment.
Net loss increased to $378,000 or $0.07 per share in 1997 from $178,000
or $0.03 per share in 1996.
LIQUIDITY AND CAPITAL RESOURCES
The Company's operations during the three months ended March 31, 1997
and 1996 provided cash of approximately $197,000 and $537,000, respectively. The
decrease in cash flow from operations between 1997 and 1996 principally reflects
the lower sales volume in the current year. As of March 31, 1997, the Company
had $403,000 in cash and cash equivalents. During 1997, the Company used
approximately $292,000 in cash to acquire property and equipment and
approximately $347,000 in cash to reduce term debt and capital lease
obligations. In March 1996, the Company completed the financing and delivery of
$1,147,000 of laboratory equipment.
9
10
The Company maintains a term and revolver loan credit agreement
("Credit Agreement") with a bank. All borrowings are secured by a lien on all
assets of the Company. The Credit Agreement provides for borrowings under the
revolver limited to 75% of qualified account receivables. As of March 31, 1997,
approximately $1,544,000 and $482,000 were outstanding under the $5,000,000
revolver and term loan, respectively. The revolver bears interest at the bank
reference rate plus 0.5% (8.75% at March 31, 1997). The term loan bears
interest at the bank reference rate plus 1.0% (9.25% at March 31, 1997). The
Credit Agreement expires in November 1997.
The Credit Agreement contains certain financial covenants which, among
others, require the Company to maintain certain levels of net worth, cash flow
and profitability and restricts the payment of dividends. In February and May
1997, PharmChem amended its Credit Agreement with respect to certain financial
covenants. As of March 31, 1997, the Company was in compliance with all
covenants of the Credit Agreement.
The Company anticipates that existing cash balances, amounts available
under existing and future credit agreements and funds to be generated from
future operations will be sufficient to fund operations and budgeted capital
expenditures through 1997.
IMPACT OF RECENT ACCOUNTING PRONOUNCEMENT
The Financial Accounting Standards Board recently issued Statement of
Financial Accounting Standards (SFAS) No. 128 "Earnings Per Share." SFAS No. 128
requires the presentation of basic earnings per share (EPS) and, for companies
with complex capital structures, diluted EPS. SFAS No. 128 is effective for
annual and interim periods ending after December 15, 1997 and requires
restatement of all prior-period EPS data presented. The Company expects basic
EPS will be equivalent to primary EPS as presented in the accompanying condensed
consolidated financial statements.
10
11
PART II. OTHER INFORMATION
Item 6. Exhibits and Reports on Form 8-K
(a) Exhibits.
Exhibit 27 - Financial Data Schedule
(b) Reports on Form 8-K
No reports on Form 8-K were filed during the quarter ended
11
12
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this Report to be signed on its behalf by the
undersigned thereunto duly authorized.
PharmChem Laboratories, Inc.
(Registrant)
Date: May 13, 1997 By: /s/ David A. Lattanzio
---------------------------
David A. Lattanzio
Chief Financial Officer and Vice President,
Finance and Administration
(Principal Financial and Accounting Officer)
12
13
EXHIBIT INDEX
Exhibit
No. Description
- -------- -----------
27 Financial Data Schedule